SCYNEXIS, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $50.6M
- Price
- $5.10
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.30%
- Volume
- 35.2K
About
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Quick stats
Shares outstanding9.9M
Computed float9.6M
Float / shares97.0%
Cash runway (months)104.4
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001178253
Websitehttps://www.scynexis.com
AI Summary
AI-generated1/8
majorbullishearnings
SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS reported Q2 2026 financial results with a cash position of $71.1 million, which management states supports a cash runway into 2029.
Operationally, the company initiated a Phase 1 study of SCY-770 for ADPKD, with topline data expected in Q3 2026, and completed dosing in the Phase 1 IV study of SCY-247.
The company noted potential to receive up to $146 million in annual net sales milestones related to the GSK relaunch of BREXAFEMME, while Q2 net income was boosted by a $14.2 million gain on warrant liabilities.
Red flags
- Q2 revenue declined significantly to $235,000 from $1.36 million in the prior year
- Net income of $7.4 million was primarily driven by a non-cash gain of $14.2 million from warrant liability adjustments rather than operations